T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Zebra Technologies
ZBRA
$18B
| $68.8M | 0.01% |
234,057
-28,691
| -11% | -$9.99M |
|
777
Halozyme
HALO
$11.4B
| $68.8M | 0.01% |
1,563,357
-1,890
| -0.1% | -$81.7K |
|
778
Sphere Entertainment
SPHR
$6.33B
| $68.7M | 0.01% |
1,305,995
+474,125
| +57% | +$32M |
|
779
iShares MSCI Global Metals & Mining Producers ETF
PICK
$2.28B
| $68.7M | 0.01% |
1,928,023
+1,010,627
| +110% | +$45M |
|
780
Boston Scientific
BSX
$74.9B
| $68.7M | 0.01% |
1,842,575
-194,886
| -10% | -$7.93M |
|
781
Winmark
WINA
$1.26B
| $68.6M | 0.01% |
350,775
-18,180
| -5% | -$3.72M |
|
782
Kimco Realty
KIM
$16.4B
| $68.6M | 0.01% |
3,468,092
-1,963,472
| -36% | -$45.1M |
|
|
CADE
783
DELISTED
Cadence Bank
CADE
| $68.4M | 0.01% |
2,913,360
+330,303
| +13% | +$8.5M |
|
|
MODV
784
DELISTED
ModivCare
MODV
| $68.3M | 0.01% |
808,041
+4,361
| +0.5% | +$440K |
|
785
Cal-Maine
CALM
$3.87B
| $68M | 0.01% |
1,377,249
-117,208
| -8% | -$5.95M |
|
786
Madison Square Garden
MSGS
$9.94B
| $67.4M | 0.01% |
446,274
+83,128
| +23% | +$13.5M |
|
|
SAGE
787
DELISTED
Sage Therapeutics
SAGE
| $67.1M | 0.01% |
2,077,534
-80,970
| -4% | -$2.71M |
|
788
General Dynamics
GD
$106B
| $66.9M | 0.01% |
302,587
-28,277
| -9% | -$6.51M |
|
|
SNCY
789
DELISTED
Sun Country Airlines
SNCY
| $66.5M | 0.01% |
3,625,598
+1,242,146
| +52% | +$29.1M |
|
790
Acadia Pharmaceuticals
ACAD
$4.89B
| $66.1M | 0.01% |
4,693,715
-285,221
| -6% | -$5.32M |
|
791
Orion
OEC
$360M
| $66.1M | 0.01% |
4,258,389
-1,048,389
| -20% | -$17.6M |
|
|
VMEO
792
DELISTED
Vimeo
VMEO
| $66M | 0.01% |
10,964,620
+1,364,656
| +14% | +$12.4M |
|
793
PTC Therapeutics
PTCT
$6.01B
| $65.7M | 0.01% |
1,640,986
-77,472
| -5% | -$2.72M |
|
794
SLB Ltd
SLB
$77.3B
| $65.6M | 0.01% |
1,835,766
-179,230
| -9% | -$7.48M |
|
|
LPRO
795
DELISTED
Open Lending Corp
LPRO
| $65.5M | 0.01% |
6,399,688
+2,277,806
| +55% | +$30.5M |
|
796
Ventas
VTR
$46.3B
| $65.3M | 0.01% |
1,269,603
+194,097
| +18% | +$10.9M |
|
|
AESC
797
DELISTED
The AES Corporation
AESC
| $64.5M | 0.01% |
753,593
-82,122
| -10% | -$7.31M |
|
798
Watsco Inc
WSO
$12.9B
| $64.2M | 0.01% |
268,820
+36,010
| +15% | +$9.48M |
|
799
LPL Financial
LPLA
$29.5B
| $64.2M | 0.01% |
347,924
-94,390
| -21% | -$17.9M |
|
|
TXNM
800
TXNM Energy Inc
TXNM
$5.91B
| $64M | 0.01% |
1,339,614
-190,392
| -12% | -$8.92M |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.